Envy Medical and Libbs Farmaceutica Announce Strategic Marketing, Sales and Distribution Agreement For Brazil
WESTLAKE VILLAGE, Calif. and SAO PAULO, July 22, 2014 /PRNewswire/ — Envy Medical and Libbs Farmaceutica today announced a strategic agreement to manufacture, market and sell Envy’s proprietary Lumixyl® Brightening Creme throughout the country of Brazil.
This is a significant milestone for Envy Medical’s professional skincare products, as it not only represents a significant agreement with Libbs, a leader in the sales and supply of pharmaceutical products, but it also represents a solid entry into the largest single skincare market outside of the United States.
“The population of Brazil possesses a strong and growing demand for an effective alternative to hydroquinone, and particularly one without the side effects associated with prescription hydroquinone,” said Curtis A. Cluff, CEO of Envy Medical, Inc. “I am particularly excited to work with Libbs, as they are a major force and a partner of unparalleled capability, ethics, and integrity.”
Products that can effectively address hyperpigmentation and photo-damage are in demand in the country, which not only has a large Latin population more genetically disposed to hyperpigmentation issues, but also the largest population of Japanese descent outside of Japan. For women (and increasingly men) of either heritage, a clear, more even skin tone is culturally important in building a stronger sense of confidence and self-esteem.
“We are pleased to bring this safe and effective skincare technology for brighter and more even skin-tone to the women and men of Brazil,” said Alcebiades de Mendonca Athayde Junior, CEO of Libbs. “The Lumixyl Brightening Creme has tested extremely well with our initial focus groups and dermatologists, both in terms of its efficacy and unique aesthetic qualities.”
The agreement was also facilitated by Aime Medical, Inc., a Clearwater, Florida-based company that acted as Envy’s international agent in identifying Libbs as the premier partner for Lumixyl in Brazil, and thereafter assisting with product launch and training activities.
Under the agreement, Libbs and Envy have collaborated in developing manufacturing capabilities for Envy products in Brazil, with Libbs leading the way in executing a tailored branding and sales strategy. The Lumixyl Brightening Creme will arrive at the Brazilian market at a suggested retail price of R$140 for a 30ml bottle. Libbs has already made the product available in over 3,000 retail drugstores and specialty pharmacies throughout Brazil with future distribution expansion plans.
ABOUT LIBBS FARMACEUTICA — Since 1958, Libbs Farmaceutica has grown into one of the top Brazilian pharmaceutical companies, with expertise in drug deployment, marketing and product management, using its a 585-member sales-force. The company’s business strategy is to pursue business where its assets can complement drug development or placement of a drug in the market. The company has established core competencies in the areas of cardiovascular, gynecology, central nervous system, dermatology, oncology, respiratory & gastroenterology. More information on Libb’s launch of Lumixyl can be found at www.lumixyl.com.br .
ABOUT ENVY MEDICAL — Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion® for deeper tissue delivery of active ingredients and better patient outcomes ( www.silkpeel.com ). Envy is also the developer of the patent pending ClarityMD Acne Solution brand of acne treatment products (www.claritymdacne.com ) and is the exclusive worldwide licensor of skin brightening peptides including Lumixyl®, developed at Stanford University ( www.lumixyl.com ). More information can be found at www.envymedical.com .
SOURCE Envy Medical
Copyright (C) 2014 PR Newswire. All rights reserved